Battling low expectations and goliath rivals, Regeneron/Sanofi add positive Libtayo data in pursuit of blockbuster status
Latecomers Regeneron and Sanofi continue to claw their way forward in the tough PD-(L)1 market. Researchers for the checkpoint allies offered a positive pivotal snapshot …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
